Vlad Schepkov
Vlad Schepkov - Activist investor reporter at StreetInsider.com/Investing.com. E-mail: [email protected]
View Older Stories View More Recent Stories
-
Apollo Endosurgery (APEN) Reiterates at Buy with $10 Price Target by Stifel, Approved ESG and REVISE are "Next Critical Growth Drivers"
-
Cantor Fitzgerald Reiterates Overweight Rating, $7 Price Target on VolitionRX (VNRX) Following Latest Nu.Q Data
-
Microsoft (MSFT) is "Preferred Name in Software, Will Be More Resilient in Downturn" - Morgan Stanley's Bullish Comments
-
Cantor Fitzgerald Reiterates Neutral Rating, $1 Price Target on TherapeuticsMD (TXMD) on Failed Acquisition
-
Latest Hutchinson (HCM) Data "Underscores Belief HCM's Pipeline is Underappreciated" - Cantor Fitzgerald Reiterates Overweight and $50 Price Target
-
Stifel Reiterates Buy Rating on Revolution (RVMD)
-
Favor the Long View on Alnylam (ALNY) Irrespective of Apollo-B Outcome - Oppenheimer Bullish with Outperform Rating, $205 Price Target
-
Vaxcyte's (PCVX) Approach Has Potential to Disrupt PCV Market - Needham & Company Reiterates Buy Rating with $52 Price Target
-
Expect Restoration in Investor Sentiment - Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
-
Moderna's (MRNA) Nipah Vaccine "Could Provide Upside to Outlook" - Brookline Reiterates Company at Buy with $506 Price Target
-
Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN)
-
Stifel Reiterates Buy Rating on Fulcrum Therapeutics (FULC) on "Surprising" CMO Departure, Anticipates Smooth Transition
-
Vertex's (VRTX) ViaCyte Acquisition "Adds Additional Shots on Goal" - BMO Capital Reiterates Stock at Outperform with $325 Price Target
-
Dawson James Reiterates Buy Rating, $5 Price Target on Can-Fite BioPharma (CANF)
-
Cowen Encouraged by Pliant's (PLRX) Data, Models $2.03B Peak Sales, Reiterates "Outperform"
-
Vertex's (VRTX) ViaCyte Acquisition not "Thesis Impacting" - Stifel Maintains Stock at Hold
-
We Encourage Investors to Acquire Nyxoah SA (NYXH) Shares - Cantor Fitzgerald Bullish on Stock Following FDA Approval of ACCESS Trial
-
Veru (VERU) is Top Pick, Little Doubt in EUA for sabizabulin - Oppenheimer Bullish on Shares Ahead of FDA Decision
-
Truth Social (DWAC) Up 17% as Elon Musk Walks Away from Twitter (TWTR) Deal
-
Truth Social (DWAC) Up 17% as Elon Musk Walks Away from Twitter (TWTR) Deal
-
Oppenheimer Reiterates Outperform Rating, $140 Price Target on Horizon Therapeutics (HZNP)
-
Intercept Pharmaceuticals (ICPT) PT Lowered to $22 at Needham & Company on "Concerns Around Overall Benefit/Safety Profile" of OCA
-
Needham & Company Reiterates Buy Rating, $6 Price Target on Cidara Therapeutics (CDTX)
-
"We Believe ARQ-151 Will Be Cleared For Take Off" - Cantor Fitzgerald Bullish on Arcutis Biotherapeutics (ARQT) Ahead of PDUFA
-
Needham & Company Reiterates Buy Rating, $150 Price Target on Sarepta Therapeutics (SRPT)
-
H.C. Wainwright Reiterates Buy Rating, $80 Price Target on Albireo Pharma (ALBO)
-
BMO Capital Reiterates Outperform Rating, $325 Price Target on Vertex (VRTX) Following VX-880 Hold Lift
-
Stifel Reiterates Buy Rating, $15 Price Target on Precigen (PGEN)
-
Meta (META) is 'Top Recession Stock' - BofA Securities Bullish on Facebook's Parent Despite Recent Weakness
-
H.C. Wainwright Reiterates Buy Rating, $13 Price Target on Astria Therapeutics (ATXS)
-
H.C. Wainwright Reiterates Buy Rating, $28 Price Target on Humanigen (HGEN)
-
H.C. Wainwright Reiterates Buy Rating, $1.25 Price Target on Akebia Therapeutics (AKBA)
-
Needham & Company Reiterates Buy Rating, $6 Price Target on Avadel Pharmaceuticals (AVDL), Sees $300M Opportunity for FT218 in Narcolepsy
-
Ultragenyx Pharma (RARE) PT Lowered to $142 at Stifel, Buy Rating Reiterated
-
Heron Therapeutics (HRTX) PT Lowered to $10 at Needham & Company
-
Trevi Therapeutics (TRVI) PT Raised to $10 at Needham & Company on Haduvio Data, "Valuation Discounts Potential"
-
Dawson James Reiterates Buy Rating, $5 Price Target on Can-Fite BioPharma (CANF) on Piclidenoson Data
-
Oppenheimer Reiterates Outperform Rating, $10 Price Target on Trevi Therapeutics (TRVI) on Solidifying PRISM Data
-
Roivant Sciences (ROIV) PT Lowered to $13 at Truist Securities on ARU-1801 Discontinuation, Buy Reiterated
-
ONO Collaboration Extension "Signifying Forward Progress" - Mizuho Securities Reiterates Buy Rating on Fate Therapeutics (FATE)
-
H.C. Wainwright Reiterates Buy Rating, $15 Price Target on Biophytis SA (BPTS)
-
ESSA Pharma (EPIX) PT Raised to $23 at Oppenheimer, Sees "Much Larger Market Opportunity" for 7386 + enzalutamide
-
Arcutis (AQRT) Has Significantly More Upside, roflumilast is Key Driver - Mizuho Securities Bullish on Stock
-
Expect Spero Therapeutics (SPRO) to Seek Partnership for tebipenem - Cowen Reiterates Market Perform on Stock
-
Etsy (ETSY) Downgraded at Needham & Company on Macro Outlook
-
Oppenheimer Reiterates Perform Rating, $94 Price Target on BioMarin Pharmaceutical (BMRN) on Positive CHMP Opinion for Roctavian
-
"See Interesting Upside Potential for REGN" - BMO Capital Reiterates Regeneron (REGN) at Outperform on NTLA Data
-
Altria (MO) Upgraded at Morgan Stanley on Price Dip, PT Lowered Following JUUL Ban
-
Stifel Reiterates Buy Rating on BioMarin Pharmaceutical (BMRN) Following Positive CHMP Recommendation for valrox
-
Tesla's (TSLA) PT Cut at Credit Suisse on Short-Term Issues, but 'Long-Term Bull Thesis Intact'
